1. Home
  2. CAPT vs NOTV Comparison

CAPT vs NOTV Comparison

Compare CAPT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

HOLD

Current Price

$0.63

Market Cap

25.1M

Sector

Finance

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.81

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPT
NOTV
Founded
2005
1974
Country
South Korea
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
29.9M
IPO Year
N/A
1997

Fundamental Metrics

Financial Performance
Metric
CAPT
NOTV
Price
$0.63
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
1.3M
1.6M
Earning Date
01-01-0001
12-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,389,944.00
$513,024,000.00
Revenue This Year
N/A
$6.26
Revenue Next Year
N/A
$45.49
P/E Ratio
N/A
N/A
Revenue Growth
84.70
4.54
52 Week Low
$0.37
$0.66
52 Week High
$1.94
$6.48

Technical Indicators

Market Signals
Indicator
CAPT
NOTV
Relative Strength Index (RSI) 37.87 36.67
Support Level $0.71 $0.84
Resistance Level $0.88 $0.95
Average True Range (ATR) 0.08 0.12
MACD -0.01 0.02
Stochastic Oscillator 6.95 39.36

Price Performance

Historical Comparison
CAPT
NOTV

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: